Immune

Immune Boost Capital (IBC) operates as a philanthropic evergreen venture fund dedicated to investing in early-stage autoimmune diagnostics and therapeutics. As a 501(c)(3) nonprofit, IBC provides catalytic proof-of-concept capital, with individual investments reaching up to $500,000 per company, aiming to bridge the funding gap between academic discoveries and commercial development. Its business model ensures that 100% of all investment returns are reinvested to sustainably advance innovation in autoimmune and inflammatory diseases. Initial capital for the fund was contributed by its parent organization, the Arthritis National Research Foundation (ANRF), which continues to support ongoing fundraising efforts. Key individuals associated with IBC include Principal Schalon Newton and Emily Stormoen, who serves as CEO of ANRF and liaison to IBC. Founding details for Immune Boost Capital are not publicly available.